Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Ischaemia reperfusion injury: mechanisms of progression to chronic graft dysfunction.

Situmorang GR, Sheerin NS.

Pediatr Nephrol. 2018 Mar 30. doi: 10.1007/s00467-018-3940-4. [Epub ahead of print] Review.

PMID:
29603016
2.

The methyltransferase SET9 regulates TGFB1 activation of renal fibroblasts via interaction with SMAD3.

Shuttleworth VG, Gaughan L, Nawafa L, Mooney CA, Cobb SL, Sheerin NS, Logan IR.

J Cell Sci. 2018 Jan 8;131(1). pii: jcs207761. doi: 10.1242/jcs.207761.

3.

Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.

Legendre CM, Campistol JM, Feldkamp T, Remuzzi G, Kincaid JF, Lommelé Å, Wang J, Weekers LE, Sheerin NS.

Transpl Int. 2017 Dec;30(12):1275-1283. doi: 10.1111/tri.13022. Epub 2017 Sep 8.

4.

Regulation of Chemokine Function: The Roles of GAG-Binding and Post-Translational Nitration.

Thompson S, Martínez-Burgo B, Sepuru KM, Rajarathnam K, Kirby JA, Sheerin NS, Ali S.

Int J Mol Sci. 2017 Aug 3;18(8). pii: E1692. doi: 10.3390/ijms18081692. Review.

5.

Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.

Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D.

Kidney Int. 2017 Nov;92(5):1261-1271. doi: 10.1016/j.kint.2017.04.028. Epub 2017 Jul 24.

6.

The NF-κB1 is a key regulator of acute but not chronic renal injury.

Fearn A, Situmorang GR, Fox C, Oakley F, Howarth R, Wilson CL, Kiosia A, Robson MG, Mann DA, Moles A, Sheerin NS.

Cell Death Dis. 2017 Jun 15;8(6):e2883. doi: 10.1038/cddis.2017.233.

7.

CCL2 nitration is a negative regulator of chemokine-mediated inflammation.

Barker CE, Thompson S, O'Boyle G, Lortat-Jacob H, Sheerin NS, Ali S, Kirby JA.

Sci Rep. 2017 Mar 14;7:44384. doi: 10.1038/srep44384.

8.

Mutations in mitochondrial DNA causing tubulointerstitial kidney disease.

Connor TM, Hoer S, Mallett A, Gale DP, Gomez-Duran A, Posse V, Antrobus R, Moreno P, Sciacovelli M, Frezza C, Duff J, Sheerin NS, Sayer JA, Ashcroft M, Wiesener MS, Hudson G, Gustafsson CM, Chinnery PF, Maxwell PH.

PLoS Genet. 2017 Mar 7;13(3):e1006620. doi: 10.1371/journal.pgen.1006620. eCollection 2017 Mar.

9.

Lysosomal protease cathepsin D; a new driver of apoptosis during acute kidney injury.

Cocchiaro P, Fox C, Tregidgo NW, Howarth R, Wood KM, Situmorang GR, Pavone LM, Sheerin NS, Moles A.

Sci Rep. 2016 Jun 7;6:27112. doi: 10.1038/srep27112.

10.

Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease.

Fox C, Cocchiaro P, Oakley F, Howarth R, Callaghan K, Leslie J, Luli S, Wood KM, Genovese F, Sheerin NS, Moles A.

Sci Rep. 2016 Feb 2;6:20101. doi: 10.1038/srep20101.

11.

Computerized clinical decision support for the early recognition and management of acute kidney injury: a qualitative evaluation of end-user experience.

Kanagasundaram NS, Bevan MT, Sims AJ, Heed A, Price DA, Sheerin NS.

Clin Kidney J. 2016 Feb;9(1):57-62. doi: 10.1093/ckj/sfv130. Epub 2015 Dec 18.

12.

Systematic assessment of the influence of complement gene polymorphisms on kidney transplant outcome.

Ermini L, Weale ME, Brown KM, Mesa IR, Howell WM, Vaughan R, Chowdhury P, Sacks SH, Sheerin NS.

Immunobiology. 2016 Apr;221(4):528-34. doi: 10.1016/j.imbio.2015.12.006. Epub 2015 Dec 12.

PMID:
26797657
13.

Thrombotic Microangiopathy as a Cause of Chronic Kidney Transplant Dysfunction: Case Report Demonstrating Successful Treatment with Eculizumab.

Iqbal Z, Wood K, Carter V, Goodship TH, Brown AL, Sheerin NS.

Transplant Proc. 2015 Sep;47(7):2258-61. doi: 10.1016/j.transproceed.2015.08.004.

PMID:
26361694
14.

Ubiquitin C-terminal hydrolase 1: A novel functional marker for liver myofibroblasts and a therapeutic target in chronic liver disease.

Wilson CL, Murphy LB, Leslie J, Kendrick S, French J, Fox CR, Sheerin NS, Fisher A, Robinson JH, Tiniakos DG, Gray DA, Oakley F, Mann DA.

J Hepatol. 2015 Dec;63(6):1421-8. doi: 10.1016/j.jhep.2015.07.034. Epub 2015 Aug 8.

15.

De Novo Donor-Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes.

Brooks AM, Carter V, Liew A, Marshall H, Aldibbiat A, Sheerin NS, Manas DM, White SA, Shaw JA.

Am J Transplant. 2015 Dec;15(12):3239-46. doi: 10.1111/ajt.13407. Epub 2015 Jul 30.

16.

An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.

Nichols EM, Barbour TD, Pappworth IY, Wong EK, Palmer JM, Sheerin NS, Pickering MC, Marchbank KJ.

Kidney Int. 2015 Dec;88(6):1314-1322. doi: 10.1038/ki.2015.233. Epub 2015 Jul 29.

17.

A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience.

Sheerin NS, Kavanagh D, Goodship TH, Johnson S.

QJM. 2016 Jan;109(1):27-33. doi: 10.1093/qjmed/hcv082. Epub 2015 Apr 21.

PMID:
25899302
18.

Behaviour of transplanted tumours and role of matching in rejection.

Khurram MA, Stamp S, Sheerin NS, Rix D, Cunningham AC, Carter N, Talbot D.

Transpl Immunol. 2015 Mar;32(2):121-5. doi: 10.1016/j.trim.2015.02.006. Epub 2015 Feb 27.

PMID:
25731677
19.

Complement activation in progressive renal disease.

Fearn A, Sheerin NS.

World J Nephrol. 2015 Feb 6;4(1):31-40. doi: 10.5527/wjn.v4.i1.31. Review.

20.

Management of hemolytic uremic syndrome.

Kavanagh D, Raman S, Sheerin NS.

F1000Prime Rep. 2014 Dec 1;6:119. doi: 10.12703/P6-119. eCollection 2014. Review.

21.

Prognosis and management of chronic kidney disease (CKD) at the end of life.

Davison R, Sheerin NS.

Postgrad Med J. 2014 Feb;90(1060):98-105. doi: 10.1136/postgradmedj-2013-132195. Epub 2013 Dec 6. Review.

PMID:
24319094
22.

Biomarkers of acute injury: predicting the long-term outcome after transplantation.

Ali S, Sheerin NS.

Kidney Int. 2013 Dec;84(6):1072-4. doi: 10.1038/ki.2013.305.

23.

Anticoagulation and kidney injury: rare observation or common problem?

Logan IR, Sheerin NS.

J Nephrol. 2013 Jul-Aug;26(4):603-5. doi: 10.5301/jn.5000292. Epub 2013 Jul 10. No abstract available.

PMID:
23843046
24.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

25.

Granulomatosis with polyangiitis presenting as ischaemic stroke.

Davison R, Sheerin NS.

JRSM Short Rep. 2012 Nov;3(11):81. doi: 10.1258/shorts.2012.012011. Epub 2012 Nov 30. No abstract available.

26.

Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation.

Brown JH, Tellez J, Wilson V, Mackie IJ, Scully M, Tredger MM, Moore I, McDougall NI, Strain L, Marchbank KJ, Sheerin NS, O'Grady J, Harris CL, Goodship TH.

Am J Transplant. 2012 Jun;12(6):1632-6. doi: 10.1111/j.1600-6143.2012.03991.x. Epub 2012 Mar 15.

27.

Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS.

Ermini L, Goodship TH, Strain L, Weale ME, Sacks SH, Cordell HJ, Fremeaux-Bacchi V, Sheerin NS.

Mol Immunol. 2012 Jan;49(4):640-8. doi: 10.1016/j.molimm.2011.11.003. Epub 2011 Dec 5.

28.

Severe intestinal oedema due to nephrotic syndrome.

Wong EK, Brady M, Sheerin NS.

QJM. 2013 Feb;106(2):191-2. doi: 10.1093/qjmed/hcr236. Epub 2012 Feb 1. No abstract available.

PMID:
22139497
29.

Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab.

Wilson CH, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM.

Transplantation. 2011 Oct 27;92(8):e42-3. doi: 10.1097/TP.0b013e318230c0bd. No abstract available.

PMID:
21989273
30.

Complement polymorphisms: geographical distribution and relevance to disease.

Ermini L, Wilson IJ, Goodship TH, Sheerin NS.

Immunobiology. 2012 Feb;217(2):265-71. doi: 10.1016/j.imbio.2011.07.020. Epub 2011 Jul 26.

PMID:
21899915
31.

Trajectories of illness in stage 5 chronic kidney disease: a longitudinal study of patient symptoms and concerns in the last year of life.

Murtagh FE, Sheerin NS, Addington-Hall J, Higginson IJ.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1580-90. doi: 10.2215/CJN.09021010. Epub 2011 Jun 16.

32.

Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction.

Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, Wong W.

Kidney Int. 2010 Aug;78(4):351-62. doi: 10.1038/ki.2010.177. Epub 2010 Jun 16.

33.

Endogenous ligands for TLR2 and TLR4 are not involved in renal injury following ureteric obstruction.

Chowdhury P, Sacks SH, Sheerin NS.

Nephron Exp Nephrol. 2010;115(4):e122-30. doi: 10.1159/000313493. Epub 2010 Apr 28.

PMID:
20424490
34.

A novel role for nephrin in the maintenance of glomerular structure.

Sheerin NS.

J Am Soc Nephrol. 2009 Aug;20(8):1661-3. doi: 10.1681/ASN.2009060596. Epub 2009 Jul 9. No abstract available.

35.

Synergy between type 1 fimbriae expression and C3 opsonisation increases internalisation of E. coli by human tubular epithelial cells.

Li K, Zhou W, Hong Y, Sacks SH, Sheerin NS.

BMC Microbiol. 2009 Mar 31;9:64. doi: 10.1186/1471-2180-9-64.

36.

C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy.

Tang Z, Lu B, Hatch E, Sacks SH, Sheerin NS.

J Am Soc Nephrol. 2009 Mar;20(3):593-603. doi: 10.1681/ASN.2008040434. Epub 2009 Jan 21.

37.

Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool.

Murphy EL, Murtagh FE, Carey I, Sheerin NS.

Nephron Clin Pract. 2009;111(1):c74-80. doi: 10.1159/000183177. Epub 2008 Dec 16.

PMID:
19088482
38.

Should complement activation be a target for therapy in renal transplantation?

Sheerin NS.

J Am Soc Nephrol. 2008 Dec;19(12):2250-1. doi: 10.1681/ASN.2008101064. Epub 2008 Nov 19. No abstract available.

39.

Illness trajectories: an important concept in the management of kidney failure.

Murtagh FE, Murphy E, Sheerin NS.

Nephrol Dial Transplant. 2008 Dec;23(12):3746-8. doi: 10.1093/ndt/gfn532. Epub 2008 Sep 22. No abstract available.

PMID:
18809974
40.

Paranoid psychosis and myoclonus: flecainide toxicity in renal failure.

Ting SM, Lee D, Maclean D, Sheerin NS.

Cardiology. 2008;111(2):83-6. doi: 10.1159/000119694. Epub 2008 Mar 31.

PMID:
18376118
41.

Reimplantation of the ureter after unilateral ureteral obstruction provides a model that allows functional evaluation.

Tapmeier TT, Brown KL, Tang Z, Sacks SH, Sheerin NS, Wong W.

Kidney Int. 2008 Apr;73(7):885-9. doi: 10.1038/sj.ki.5002797. Epub 2008 Jan 16.

42.

Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury.

Sheerin NS, Risley P, Abe K, Tang Z, Wong W, Lin T, Sacks SH.

FASEB J. 2008 Apr;22(4):1065-72. Epub 2007 Nov 26.

PMID:
18039928
43.

The classical complement pathway plays a critical role in the opsonisation of uropathogenic Escherichia coli.

Li K, Sacks SH, Sheerin NS.

Mol Immunol. 2008 Feb;45(4):954-62. Epub 2007 Sep 17.

PMID:
17870166
44.

Mechanisms of disease: the complement system in renal injury--new ways of looking at an old foe.

Brown KM, Sacks SH, Sheerin NS.

Nat Clin Pract Nephrol. 2007 May;3(5):277-86. Review.

PMID:
17457361
45.

Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5.

Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE.

Nephrol Dial Transplant. 2007 Jul;22(7):1955-62. Epub 2007 Apr 4.

PMID:
17412702
46.
47.
48.

Influence of donor C3 allotype on late renal-transplantation outcome.

Brown KM, Kondeatis E, Vaughan RW, Kon SP, Farmer CK, Taylor JD, He X, Johnston A, Horsfield C, Janssen BJ, Gros P, Zhou W, Sacks SH, Sheerin NS.

N Engl J Med. 2006 May 11;354(19):2014-23.

49.

Deficiency of C4 from donor or recipient mouse fails to prevent renal allograft rejection.

Lin T, Zhou W, Farrar CA, Hargreaves RE, Sheerin NS, Sacks SH.

Am J Pathol. 2006 Apr;168(4):1241-8.

50.

Accumulation of immune complexes in glomerular disease is independent of locally synthesized c3.

Sheerin NS, Abe K, Risley P, Sacks SH.

J Am Soc Nephrol. 2006 Mar;17(3):686-96. Epub 2006 Feb 1.

Supplemental Content

Loading ...
Support Center